1.Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113(6), e85–151.
2. , , . How does breast cancer mortality compare with that of other cancers and cardiovascular diseases at different ages in US women?J Womens Health Gend Based Med 2000; 9, 999–1000.
3. , , et al. Evidence-based guidelines for cardiovascular disease prevention in women; AHA scientific statement, consensus panel statement. Circulation 2004; 99, 2480–2484.
4. , , , , , . Some factors associated with the development of coronary heart disease; six years' follow-up experience in the Framingham Study. Am J Public Health 1959; 49, 1349–1356.
5. , , , , , Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97, 1837–1847.
6. , , , The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332, 1758–1766.
7. The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990; 592, 263–271.
8. , , , et al. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96, 2468–2482.
9. . Summary of Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel II). J Am Med Assoc 1993; 269, 3015–3023.
10. , , , Ethnic and socioeconomic differences in cardiovascular disease risk factors. J Am Med Assoc 1998; 280, 356–362.
11. . The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42, 1206.
12. , , , et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized controlled trials. Ann Intern Med 1997; 126, 761–767.
13. , . Drug treatment of hyperlipidemia in women. J Am Med Assoc 2004; 291, 2243–2252.
14. , et al. Serum cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Survey, 1999 to 2000. Circulation 2003; 107, 2185–2189.
15. , , , et al. Cholesterol and heart disease in older persons and women. Ann Epidemiol 1992; 2, 161–176.
16. , , , Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153, 2209–2216.
17. , , , , High-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinic Prevalence Study. Am J Epidemiol 1990; 131, 32–47.
18. , Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3(2), 213–219.
19. , , Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81(4A), 7B–12B.
20. . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,538 high-risk individuals: a randomized placebo controlled trial. Lancet 2002; 360, 7–22.
21. . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III). J Am Med Assoc 2001; 285, 2486–2497.
22. . Lipid Management in Adults, Bloomington, MN: ICSI, 2006.
23. , , , et al. Relative and absolute excess risk of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987; 317, 1303–1309.
24.National Health Interview Survey (NHIS), January–June 2006. Bethesda, MD: National Center for Health Statistics.
25. , , Cigarette smoking and age at first acute myocardial infarction, and influence of gender and extent of smoking. Am J Cardiol 1993; 71, 1439–1442.
26. , , . Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322, 213–217.
27. , , , . Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160(7), 939–944.
28. , , Mortality in non-insulin-dependent diabetes. In Diabetes in America, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1995, pp. 249–250.
29. , . Risk modification in the diabetic patient. In , , , , eds., Prevention of Myocardial Infarction, New York: Oxford University Press, 1996, pp. 241–273.
30. , et al. Diabetes and decline in heart disease mortality in US adults. J Am Med Assoc 1999; 281, 1291–1297.
31. . The Third National Health and Nutrition Examination Survey (NHANES III 1988–94) Reference Manuals and Reports. Bethesda, MD: National Center for Health Statistics, 1996.
32. , , , et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110, 1251–1257.
33. , , , , , Physical activity and mortality in postmenopausal women. J Am Med Assoc 1997; 277, 1287–1292.
34. , , , , Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343, 16–22.
36. , , , , , Physical fitness and all-cause mortality; a prospective study of healthy men and women. J Am Med Assoc 1989; 262, 2395–2401.
37. , . Weight, weight gain, activity, and major illnesses: the Nurses' Health Study. Int J Sports Med 1997; 18(suppl 3), S162–S170.
38. , , , Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. J Am Med Assoc 1994; 272, 205–211.
39. , , , et al. A prospective study of obesity and the risk of coronary heart disease in women. N Engl J Med 1990; 322, 882–889.
40. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149, 1514–1520.
41. . Regional patterns of fat distribution. Ann Intern Med 1985; 103, 994–995.
42. Exercise is not an effective weight loss modality in women. J Am Coll Nutr 1993; 12, 363–367.
43. , , , , , A prospective, observational study on hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133, 933–941.
44Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Am Med Assoc 1995; 273, 199–208.
45. , , , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280, 605–613.
46.Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288, 321–333.
47. , , , Coronary heart disease events associated with hormone therapy in younger and older women, a meta-analysis. J Gen Intern Med 2006; 21(4), 363–366.
48. , , , et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109, 672–693.
49. . Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy. Prev Cardiol 2004; 7, 131–136.
50. . Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002; 86, 5–18.
51. , , , et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR) trial. Am J Cardiol 2003; 92, 152–160.
, , , et al
., for the American Heart Association Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation
. American Heart Association website, available at http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA
53. . Final report from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321, 129–135.
54. , , , et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13), 1293–1304.
55. . Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308, 81–106.
56. . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2, 349.
57. , , , et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126, 513S.
59. , , , . Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136, 161–172.
60. , , , et al. Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina. J Am Coll Cardiol 1998; 31, 957.
61. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000; 101, 1097.
62. , , , et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328, 1444.
63. , Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357, 89.
64MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360, 23.
65. , , , Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study. Ann Emerg Med 1993; 22, 579–582.
66. , , , , , , et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342, 1163–1170.
67. , , , , , , et al. Age and sex differences in presentation of symptoms among patients with acute coronary disease: the REACT trial. Coron Artery Dis 2000; 11, 399–407.
68. , , , , , Gender differences in symptom presentation association with coronary heart disease. Am J Cardiol 1999: 84, 396–399.
69. , , , , , , et al. A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med 1988; 318, 797–803.
70. , , , et al. Chest pain in women: clinical, investigative, and prognostic features. Br Med J 1994; 308, 883–886.
71. , , , , , , Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J 2000; 139, 649–653.
72. , , , , Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Cardiol 1996; 78, 9–14.
73. Angina pectoris in a contemporary population: characteristcs and therapeutic implications. TIDES Investigators. Cardiovasc Drugs Ther 1998; 12(Supp 3), 211–216.
74. Gender-specific physiology: how real is it? How important is it?Int J fertil 1997; 42(1), 19–29.
75. , , , , , , et al. Depression and type A behavior pattern in patients with coronary artery disease: relationships to painful versus silent myocardial ischemia and B-endorphin responses during exercise. Psychosom Med 1991; 53, 669–683.
76. , , , , , , et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104, 2024–2028.
77. , Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991; 325(4), 221–225.
78. , , , , , , et al. Sex differences in evaluation and outcome of unstable angina. J Am Med Assoc 2000; 283(5), 646–652.
79. , , , et al. Enhancing quality of care for acute myocardial infarction: shifting the focus of improvement form key indicators to process of care and tool use. J Am Coll Cardiol 2004; 43, 2166–2173.
80. , , , et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. J Am Med Assoc 2002; 287, 1269–1276.
81. , , , et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100, 1016–1030.
Guideline Update for Exercise Testing: a Report of the American College of Cardiology/AHA Task Force on Practice Guidelines. www.americanheart.org
83. , , , et al. Angiographic prevalence of high risk coronary artery disease in patient subsets (CASS). Circulation 1981; 64, 360–367.
84. Noninvasive diagnosis of CAD in women. J Myocard Ischem 1995; 7, 263–268.
85. , , , et al. Guidelines for exercise testing: a report of the Joint American College of Cardiology/American Heart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on Exercise Testing). Circulation 1986; 74(3), 653–667A.
86. , , , et al. Relation of results of exercise stress tests in young women to phases of the menstrual cycle. Am J Cardiol 1988; 61(1), 197–199.
87. , , , et al. Noninvasive diagnostic test choices for the evaluation of coronary artery disease in women: a multivariate comparison of cardiac fluoroscopy, exercise electrocardiography and exercise thallium myocardial perfusion scintigraphy. J Am Coll Cardiol 1984; 4(1), 8–16.
88. , , , et al. Exercise echocardiography is an accurate and cost-effective technique for detection of coronary artery disease in women. J Am Coll Cardiol 1995; 26, 335–341.
89. , , , et al. Long-term prognostic value of exercise testing in men and women from the Coronary Artery Surgery Study (CASS) registry. Am J Cardiol 1995; 75(14), 865–870.
90. , , , Exercise testing in women with chest pain. Are there additional exerice characteristics that predict true positive test results?Chest 1989; 95, 139–144.
91. , , , , , , Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. J Am Med Assoc 2003; 290, 1600–1607.
92. , , , , , Cardiac syndrome X: clinical characteristics and left ventricular function. J Am Coll Cardiol 1995; 25, 807–814.
93. , , , , Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999; 341, 217–225.
94. , , , , et al. for the National Registry of Myocardial Infarction (NRMI) Investigators. High MI mortality in women: gender or age?JACC 1993; 21(Suppl A), 347A.
95. , , , et al. Comparisons of characteristics and outcomes among women and men with acute MI treated with thrombolytic therapy. J Am Med Assoc 1996; 275, 777–782.
96. , , , et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med 1999; 341, 226–232.
97. , , , et al. Differences between men and women in hospital mortality associated with coronary artery bypass graft surgery. Circulation 1993; 88, 2104–2110.
98. , , , et al. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation 2002; 105, 1176–1181.
99. Coronary revascularization in women in 2003: sex revisited. Circulation 2003; 107, 375.
100. , , , et al. Better outcome for women compared with men undergoing coronary revascularization a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1998; 98, 1279–1285.
101. , , , et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2002; 39, 1606–1614.
102. , , , et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. J Am Coll Cardiol 2000; 36, 381–386.
103. , , , et al. Sex differences in neurological outcomes and mortality after cardiac surgery: a Society of Thoracic Surgery National Database report. Circulation 2001; 103, 2133–2137.
104. , , , et al. Mortality, risk indicators of death, mode of death and symptoms of angina pectoris during 5 years after coronary artery bypass grafting in men and women. J Intern Med 2000; 247, 500–506.
105. , , , et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346, 1173–780.
106. , , , et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349, 1315–1323.
107. , , , et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103, 192–195.